ATE162403T1 - Modifizierte antikörper mit kontrollierter clearance-zeit - Google Patents
Modifizierte antikörper mit kontrollierter clearance-zeitInfo
- Publication number
- ATE162403T1 ATE162403T1 AT91918652T AT91918652T ATE162403T1 AT E162403 T1 ATE162403 T1 AT E162403T1 AT 91918652 T AT91918652 T AT 91918652T AT 91918652 T AT91918652 T AT 91918652T AT E162403 T1 ATE162403 T1 AT E162403T1
- Authority
- AT
- Austria
- Prior art keywords
- modified antibodies
- clearance time
- controlled clearance
- modified
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/579,375 US5194594A (en) | 1990-09-07 | 1990-09-07 | Modified antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE162403T1 true ATE162403T1 (de) | 1998-02-15 |
Family
ID=24316640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT91918652T ATE162403T1 (de) | 1990-09-07 | 1991-08-28 | Modifizierte antikörper mit kontrollierter clearance-zeit |
Country Status (8)
Country | Link |
---|---|
US (1) | US5194594A (de) |
EP (2) | EP0783894A1 (de) |
JP (2) | JP3549525B2 (de) |
AT (1) | ATE162403T1 (de) |
AU (1) | AU649079B2 (de) |
CA (1) | CA2090700C (de) |
DE (1) | DE69128791T2 (de) |
WO (1) | WO1992004052A1 (de) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5356784A (en) * | 1993-03-30 | 1994-10-18 | Terrapin Technologies, Inc. | Determination of concentration by affinity titration |
WO1994023298A1 (en) * | 1993-03-30 | 1994-10-13 | Terrapin Technologies, Inc. | Determination of concentration by affinity titration and competitive displacement in drug delivery |
CA2242750C (en) * | 1996-01-11 | 2007-03-27 | Leslie A. Khawli | Antibodies with reduced net positive charge |
US5990286A (en) * | 1996-12-18 | 1999-11-23 | Techniclone, Inc. | Antibodies with reduced net positive charge |
JP2001512480A (ja) * | 1997-02-19 | 2001-08-21 | セントコア,インコーポレイテッド | 持続的薬物送達およびそれに有用な組成物 |
US7381413B1 (en) * | 1998-04-17 | 2008-06-03 | University Of Vermont And State Agricultural College | Methods and products related to metabolic interactions in disease |
EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
DK1177312T3 (da) | 1999-04-28 | 2008-02-25 | Genetics Inst Llc | Humane GIL-19/AE289-proteiner og polynukleotider kodende derfor |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
EP1792991A1 (de) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Humane Antikörper gegen CTLA-4 und deren Verwendungen |
AU7404800A (en) * | 1999-09-30 | 2001-04-30 | Novo Nordisk A/S | A method for preparing conjugates between an antigen and mucosal binding component |
EP1254179A4 (de) * | 2000-01-24 | 2005-06-01 | Univ Columbia | In vivo screen unter verwendung von chemischen induktoren |
US20020168737A1 (en) * | 2001-01-24 | 2002-11-14 | Cornish Virginia W. | Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization |
US20030138785A1 (en) * | 2001-12-21 | 2003-07-24 | Stephan Kopytek | In vivo protein screen based on enzyme-assisted chemically induced dimerization ("CID") |
US6578724B1 (en) * | 2001-12-29 | 2003-06-17 | United States Can Company | Connector for use in packaging aerosol containers |
US7135174B2 (en) * | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
WO2003062278A1 (en) | 2002-01-25 | 2003-07-31 | G2 Therapies Ltd | MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR |
EP1503794B9 (de) * | 2002-04-12 | 2012-09-19 | Medarex, Inc. | Behandlungsverfahren unter verwendung von ctla-4 antikörpern |
US7083918B2 (en) * | 2002-04-24 | 2006-08-01 | The Trustees Of Columbia University In The City Of New York | Bacterial small-molecule three-hybrid system |
WO2004035608A2 (en) * | 2002-10-18 | 2004-04-29 | Abgenix, Inc. | System and method for cleaving antibodies |
MXPA05005921A (es) | 2002-12-02 | 2005-10-19 | Abgenix Inc | Anticuerpos dirigidos a factor de necrosis tumoral y sus usos. |
WO2004084823A2 (en) | 2003-03-19 | 2004-10-07 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
ATE402947T1 (de) | 2003-06-25 | 2008-08-15 | Peregrine Pharmaceuticals Inc | Verfahren und vorrichtung zur kontinuierlichen radioaktiven markierung von proteinen im grossen massstab |
EP1638606B1 (de) | 2003-06-27 | 2016-01-06 | Amgen Fremont Inc. | Antikörper gegen deletionsmutanten des epidermalen wachstumsfaktor-rezeptors und ihre anwendungen |
WO2006008639A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
DK1827492T3 (da) | 2004-11-30 | 2010-11-22 | Curagen Corp | Antistoffer rettet mod GPNMB og anvendelser deraf |
TW200635946A (en) | 2004-12-20 | 2006-10-16 | Abgenix Inc | Binding proteins specific for human matriptase |
WO2007059082A1 (en) | 2005-11-10 | 2007-05-24 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
EP3312196B1 (de) | 2005-03-23 | 2019-07-17 | Genmab A/S | Antikörper gegen cd38 zur behandlung von multiplem myelom |
EP2384767B1 (de) | 2005-03-24 | 2016-03-09 | Millennium Pharmaceuticals, Inc. | OV064-bindende Antikörper und Verfahren zu deren Verwendung |
AU2006278260B2 (en) * | 2005-08-08 | 2012-03-08 | Onconon, Llc. | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
EP1954311A4 (de) | 2005-12-07 | 2009-12-23 | Medarex Inc | Ctla-4-antikörper-dosierungseskalationstherapien |
RS52357B (en) | 2005-12-13 | 2012-12-31 | Medimmune Limited | BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE |
WO2007083984A1 (en) | 2006-01-23 | 2007-07-26 | Gwangju Institute Of Science And Technology | Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same |
KR20090029184A (ko) * | 2006-04-07 | 2009-03-20 | 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 항체 조성물 및 신생물성 질병의 치료 방법 |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
CN101506237B (zh) * | 2006-08-22 | 2014-05-07 | G2炎症私人有限公司 | 具有改进性能的抗-C5aR抗体 |
TR201910145T4 (tr) | 2006-09-26 | 2019-08-21 | Genmab As | Tümörlerin tedavi edilmesine yönelik anti-CD38 artı kortikosteroidler artı bir kortikosteroid-olmayan kemoterapötik. |
US20090162858A1 (en) * | 2007-09-18 | 2009-06-25 | Cornish Virginia W | Orthogonal chemical inducer of dimerization |
WO2009103113A1 (en) * | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | HUMANIZED ANTI-C5aR ANTIBODIES |
EP2927244A1 (de) | 2008-09-19 | 2015-10-07 | MedImmune, LLC | Gegen DLL4 gerichtete Antikörper und ihre Verwendung |
US20110268757A1 (en) | 2008-12-03 | 2011-11-03 | Institut Pasteur | Use of phenol-soluble modulins for vaccine development |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
CA2748158A1 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
RU2605318C2 (ru) | 2009-05-05 | 2016-12-20 | Новиммун С.А. | Анти-il-17f антитела и способы их применения |
KR101962476B1 (ko) | 2009-07-03 | 2019-03-26 | 아비펩 피티와이 리미티트 | 면역성 접합체 및 그 제조방법 |
EA030827B1 (ru) | 2009-10-23 | 2018-10-31 | Милленниум Фармасьютикалз, Инк. | Анти-gcc антитело и его применения |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
EP2516462B1 (de) | 2009-12-23 | 2015-05-06 | Avipep Pty Ltd | Immunkonjugate und verfahren zu ihrer herstellung |
AU2011261161A1 (en) | 2010-06-01 | 2013-01-10 | Ludwig Institute For Cancer Research Limited | Antibodies directed to the unprocessed receptor tyrosine kinase c-Met |
SI2580243T1 (sl) | 2010-06-09 | 2020-02-28 | Genmab A/S | Protitelesa proti humanemu CD38 |
EP3214442A1 (de) | 2010-10-25 | 2017-09-06 | F. Hoffmann-La Roche AG | Behandlung von gastrointestinalen entzündungen und psoriasis und asthmaentzündung und psoriasis a |
NZ609567A (en) | 2010-11-05 | 2015-05-29 | Transbio Ltd | Markers of endothelial progenitor cells and uses thereof |
AU2011349049B2 (en) | 2010-12-22 | 2016-08-11 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
US9211302B2 (en) | 2011-01-17 | 2015-12-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulation of LRCH4 activity and therapeutic application thereof |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
EP3103810A3 (de) | 2011-04-21 | 2017-03-08 | Garvan Institute of Medical Research | Modifizierte moleküle mit variablen domänen sowie herstellungs- und verwendungsverfahren dafür |
CN103596982B (zh) | 2011-06-06 | 2016-11-02 | 诺沃—诺迪斯克有限公司 | 治疗性抗体 |
DK2744931T3 (en) | 2011-08-18 | 2018-08-06 | Affinity Biosciences Pty Ltd | SOLUBLE POLYPEPTIDES |
SG11201402365RA (en) | 2011-11-16 | 2014-06-27 | Amgen Inc | Methods of treating epidermal growth factor deletion mutant viii related disorders |
KR102100388B1 (ko) | 2012-02-06 | 2020-04-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
JP2016507555A (ja) | 2013-02-06 | 2016-03-10 | インヒブルクス エルピー | 血小板非減少性かつ赤血球非減少性cd47抗体及びその使用方法 |
EP3705494A3 (de) | 2013-08-14 | 2020-12-09 | Sachdev Sidhu | Antikörper gegen frizzled proteine und verwendung davon |
WO2015136469A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
EP3116906A1 (de) | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Für lg1-3 spezifische anti-laminin4-antikörper |
TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法 |
EP3116907A1 (de) | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Für lg4-5 spezifische anti-laminin4-antikörper |
US9738702B2 (en) | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
JP2017518737A (ja) | 2014-04-21 | 2017-07-13 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | SYK標的治療薬のための抗pSYK抗体分子及びその使用 |
JP6701162B2 (ja) | 2014-07-11 | 2020-05-27 | ゲンマブ エー/エス | Axlに結合する抗体 |
WO2016061632A1 (en) | 2014-10-23 | 2016-04-28 | La Trobe University | Fn14-binding proteins and uses thereof |
CN107427574B (zh) | 2015-01-09 | 2022-02-08 | 阿达尔塔有限公司 | Cxcr4结合分子 |
KR20180002782A (ko) | 2015-05-06 | 2018-01-08 | 얀센 바이오테크 인코포레이티드 | 전립선 특이적 막 항원(psma) 이중특이성 결합제 및 그의 용도 |
ES2784685T3 (es) | 2015-07-10 | 2020-09-29 | Genmab As | Productos conjugados de anticuerpo-fármaco específicos de AXL para el tratamiento del cáncer |
WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
CA2998716A1 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
US10889638B2 (en) | 2016-05-02 | 2021-01-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
KR20230070336A (ko) | 2016-05-02 | 2023-05-22 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
WO2018204546A2 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
US11208482B2 (en) | 2018-11-26 | 2021-12-28 | Forty Seven, Inc. | Humanized antibodies against c-Kit |
BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
EP3909601A1 (de) | 2020-05-11 | 2021-11-17 | LeukoCom GmbH | Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4698320A (en) * | 1984-06-26 | 1987-10-06 | Kabushiki Kaisha Toshiba | Aluminum nitride sintered body |
EP0214995B1 (de) * | 1985-03-04 | 1990-12-27 | Dana Farber Cancer Institute | Immunotoxin und herstellung |
NO167124C (no) * | 1985-04-03 | 1991-10-09 | Du Pont Merck Pharma | Fremgangsmaate for fremstilling av et spormerket konjugat av metallthionein og biologisk aktivt molekyl. |
US4724213A (en) * | 1985-05-24 | 1988-02-09 | Northwestern University | Murine hybridoma Lym-1 and diagnostic antibody produced thereby |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4831122A (en) * | 1986-01-09 | 1989-05-16 | Regents Of The University Of Minnesota | Radioimmunotoxins |
US4771128A (en) * | 1986-10-10 | 1988-09-13 | Cetus Corporation | Method of purifying toxin conjugates using hydrophobic interaction chromatography |
US4859449A (en) * | 1987-09-14 | 1989-08-22 | Center For Molecular Medicine And Immunology | Modified antibodies for enhanced hepatocyte clearance |
ATE130197T1 (de) * | 1988-06-14 | 1995-12-15 | Cell Med Inc | Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren. |
IE62463B1 (en) * | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
US5019393A (en) * | 1988-08-03 | 1991-05-28 | New England Deaconess Hospital Corporation | Biocompatible substance with thromboresistance |
GB8903021D0 (en) * | 1989-02-10 | 1989-03-30 | Celltech Ltd | Chemical compounds |
GB8903022D0 (en) * | 1989-02-10 | 1989-03-30 | Celltech Ltd | Chemical compounds |
CA1339415C (en) * | 1989-08-24 | 1997-09-02 | Milton David Goldenberg | Detection and treatment of infections with immunoconjugates |
US5011676A (en) * | 1990-03-27 | 1991-04-30 | Thomas Jefferson University | Method to directly radiolabel antibodies for diagnostic imaging and therapy |
US5043340A (en) * | 1990-04-03 | 1991-08-27 | Eli Lilly And Company | Derivatives of 4-desacetyl VLB C-3 carboxhydrazide |
-
1990
- 1990-09-07 US US07/579,375 patent/US5194594A/en not_active Expired - Lifetime
-
1991
- 1991-08-28 CA CA002090700A patent/CA2090700C/en not_active Expired - Lifetime
- 1991-08-28 DE DE69128791T patent/DE69128791T2/de not_active Expired - Lifetime
- 1991-08-28 JP JP51781791A patent/JP3549525B2/ja not_active Expired - Lifetime
- 1991-08-28 AT AT91918652T patent/ATE162403T1/de not_active IP Right Cessation
- 1991-08-28 AU AU87541/91A patent/AU649079B2/en not_active Expired
- 1991-08-28 WO PCT/US1991/006164 patent/WO1992004052A1/en active IP Right Grant
- 1991-08-28 EP EP96117696A patent/EP0783894A1/de not_active Ceased
- 1991-08-28 EP EP91918652A patent/EP0550663B1/de not_active Expired - Lifetime
-
2004
- 2004-01-21 JP JP2004013610A patent/JP3936339B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2090700C (en) | 2001-10-30 |
EP0550663A1 (de) | 1993-07-14 |
WO1992004052A1 (en) | 1992-03-19 |
EP0783894A1 (de) | 1997-07-16 |
AU649079B2 (en) | 1994-05-12 |
US5194594A (en) | 1993-03-16 |
JP2004210793A (ja) | 2004-07-29 |
DE69128791T2 (de) | 1998-05-28 |
JP3936339B2 (ja) | 2007-06-27 |
DE69128791D1 (de) | 1998-02-26 |
JP3549525B2 (ja) | 2004-08-04 |
CA2090700A1 (en) | 1992-03-08 |
JPH06500563A (ja) | 1994-01-20 |
EP0550663B1 (de) | 1998-01-21 |
AU8754191A (en) | 1992-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69128791T2 (de) | Modifizierte antikörper mit kontrollierter clearance-zeit | |
NO901986D0 (no) | Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler. | |
FI950062A (fi) | Proteiinien foroaktivaatio konjugaatiotarkoituksia varten | |
ATE192047T1 (de) | Bicylclische, polyazamakrocyclocarbonsäure- komplexe, konjugate, herstellung und verwendung als kontraststoffe | |
FI904974A0 (fi) | Tvaerbundna antikroppar och processer foer deras framstaellning. | |
DE3585061D1 (de) | Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnose- oder therapieverfahren bezueglich krebskrankheiten. | |
FI891718A (fi) | Foerfarande foer att befria cellblandningar och vaevnader av icke-oenskade populationer. | |
ATE160943T1 (de) | Bicycloazamakrocyclophosphon-säure, komplexe, konjugate, kontrastmittel und herstellung | |
ATE249243T1 (de) | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat | |
IL95407A0 (en) | Reagent for the detection of fibrinolytic activity | |
DE3689299D1 (de) | Verwendung von amphipatischen Molekülen zur Radiodarstellung und Therapie mittels monoklonaler oder polyklonaler Antikörperkonjugate. | |
EA200100311A1 (ru) | Бифункциональные антитела и их применение для прицельной доставки противоопухолевых средств | |
MY109649A (en) | Bicyclopol yazamacrocyclocarboxylic acid complexes, and conjugates, processes for their prepration, and use as contrast agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |